We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
+8.75%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$44.9M
AUM Growth
-$9.95M
Cap. Flow
-$12.6M
Cap. Flow %
-28.07%
Top 10 Hldgs %
83.47%
Holding
31
New
4
Increased
3
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$1.38M
2
BLUE
bluebird bio
BLUE
+$748K
3
IRON icon
Disc Medicine
IRON
+$362K
4
BNTC icon
Benitec Biopharma
BNTC
+$349K
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$346K

Top Sells

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$2.87M
2
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$1.98M
3
INSM icon
Insmed
INSM
+$1.34M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$1.15M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$1.05M

Sector Composition

Rank Sector Weight
1 Healthcare 52.66%
2 Technology 0.1%
3 Communication Services 0.04%
4 Consumer Discretionary 0%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BATL icon
26
Battalion Oil
BATL
$31.9M
– –
-7,423
Closed -$24.8K
NBIX icon
27
Neurocrine Biosciences
NBIX
$16.8B
– –
-8,350
Closed -$1.15M
XBI icon
28
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-50,000
Closed -$4.64M
BFIIW
29
DELISTED
BurgerFi International, Inc. Warrant
BFIIW
– –
-2,083,438
Closed -$26.3K
BFI
30
DELISTED
BurgerFi International, Inc. Common Stock
BFI
– –
-2,745,938
Closed -$557K
NFYS
31
DELISTED
Enphys Acquisition Corp.
NFYS
– –
-78,125
Closed -$858K
1
2

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
BCPE
Bain Capital Public Equity Boston, Massachusetts $18M AUM 35.19% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $18.1M AUM 29.08% 1-Year Est. Return

Lion Point Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Lion Point Capital held 31 positions worth $44.9M, down 18% from $54.9M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Lion Point Capital withdrew a net $12.6M in Q3 2024, closing 6 positions and reducing 8 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $1.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 51% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Lion Point Capital opened a new position in Biohaven worth $1.77M.

  • Lion Point Capital's largest Q3 2024 buy was Biohaven: 35,400 shares worth $1.77M.
  • Lion Point Capital added most to bluebird bio in Q3 2024, an estimated $748K increase.
  • Lion Point Capital's biggest Q3 2024 reduction was Ardelyx, cutting an estimated $2.87M.
  • Lion Point Capital fully exited Neurocrine Biosciences in Q3 2024, selling an estimated $1.15M.
  • Lion Point Capital's ten largest holdings make up 83% of its $44.9M portfolio in Q3 2024.
  • Lion Point Capital opened 4 new positions and closed 6 in Q3 2024.
  • Lion Point Capital's portfolio value fell 18% quarter-over-quarter to $44.9M.

Based on Lion Point Capital's 13F filing for Q3 2024, filed 14 Nov 2024.